Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Alteryx, Lowers Price Target to $62

Needham analyst Mike Cikos maintains Alteryx (NYSE:AYX) with a Buy and lowers the price target from $80 to $62.

byBenzinga Newsdesk

November 2, 2022

1 minute read

Needham analyst Mike Cikos maintains Alteryx (NYSE:AYX) with a Buy and lowers the price target from $80 to $62.

Kroger Stock Jumps After Q3 Earnings: Analysts React To Booming Grocery Demand, Food Inflation

By Wayne Duggan

Today, 10:51 PM

Shares of Kroger Co (NYSE: KR) pulled back on Friday after the grocery stock’s big post-earnings gains on Thursday.

HC Wainwright & Co. Reiterates Buy on TRX Gold, Maintains $1.1 Price Target

By Benzinga Newsdesk

Today, 10:51 PM

HC Wainwright & Co. analyst Heiko Ihle reiterates TRX Gold (AMEX:TRX) with a Buy and maintains $1.1 price target.

TRX

Deutsche Bank Initiates Coverage On American Woodmark with Sell Rating, Announces Price Target of $45

By Benzinga Newsdesk

Today, 10:51 PM

Deutsche Bank analyst Joe Ahlersmeyer initiates coverage on American Woodmark (NASDAQ:AMWD) with a Sell rating and announces Price Target of $45.

AMWD

Selecta In-Licenses Rights To IgG Protease Platform

By Vandana Singh

Today, 10:51 PM

Selecta Biosciences Inc (NASDAQ:SELB) has announced a strategic licensing agreement to advance a next-generation IgG protease. The partnership leverages Genovis’ immunoglobulin…

SELB

Needham Maintains Buy on Alteryx, Lowers Price Target to $62

Related Posts

Kroger Stock Jumps After Q3 Earnings: Analysts React To Booming Grocery Demand, Food Inflation

HC Wainwright & Co. Reiterates Buy on TRX Gold, Maintains $1.1 Price Target

Deutsche Bank Initiates Coverage On American Woodmark with Sell Rating, Announces Price Target of $45

Selecta In-Licenses Rights To IgG Protease Platform